Should Nilvad turn out to be the first medication that interrupts the progression of Alzheimer's to any degree, there would be an instant pent up demand for it. Archer could easily license it to one or more pharmas for hundreds of millions, IN MY OPINION! That funding could easily permit a spinning off of Archer and merger with a reincorporated Rock Creek. Would former Rock Creek shareholders be retained? My guess is "yes", because we are shareholders along with Jonnie Williams. But only time will tell us if this is just a pipe dream!
News 
Market Data 
Discover 
